All Stories

  1. PCSK6 in Pathophysiology and Its Potential Involvement in Pulmonary Fibrosis
  2. The Role of the Protease PCSK6 in Pathophysiology and Its Potential Role in Pulmonary Fibrosis
  3. Epithelial PCSK6 Promotes Proliferation and Decreases Collagen Deposition by Fibroblasts Potentially via MMP Activation
  4. Identification of C/EBPδ‐Modifying Compounds as Potential Anticancer Agents Using a High‐Throughput Drug Screen
  5. Identification of pancreatic cancer-specific protease substrates for protease-dependent targeted delivery
  6. Hypoxia Abrogates Tumor-Suppressive Activities of C/EBPδ in Pancreatic Cancer
  7. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer
  8. PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?
  9. C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC
  10. C/EBPδ Suppresses Motility-Associated Gene Signatures and Reduces PDAC Cell Migration
  11. Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by enhancing profibrotic macrophage activation
  12. Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome
  13. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview
  14. Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner
  15. CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs
  16. Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation
  17. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer
  18. Protease‐activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma
  19. Alveolar epithelial TET2 is not involved in the development of bleomycin‐induced pulmonary fibrosis
  20. Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion
  21. Thrombin-mediated vasculogenic mimicry: important lessons to improve anticoagulant therapy of selected cancer patients
  22. CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells
  23. Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?
  24. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?
  25. Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
  26. Pharmacological PAR‐1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy
  27. Smoothened-dependent and -independent pathways in mammalian noncanonical Hedgehog signaling
  28. Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debate
  29. Protease‐activated receptor‐1 impedes prostate and intestinal tumor progression in mice: comment
  30. Protease-activated receptor-1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy
  31. Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma
  32. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer
  33. Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
  34. Protease-Activated Receptor 2 Facilitates Bacterial Dissemination in Pneumococcal Pneumonia
  35. Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent manner
  36. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer
  37. Targeting coagulation factor receptors – protease‐activated receptors in idiopathic pulmonary fibrosis
  38. Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer
  39. Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice
  40. Detrimental role for CCAAT/enhancer binding protein δ in blood-borne brain infection
  41. Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice
  42. High endogenous activated protein C levels attenuates bleomycin‐induced pulmonary fibrosis
  43. CCAAT/enhancer-binding protein δ (C/EBPδ) aggravates inflammation and bacterial dissemination during pneumococcal meningitis
  44. Lipid droplets hypertrophy: a crucial determining factor in insulin regulation by adipocytes
  45. Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis
  46. Authors' reply-Re: Shi et al. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol 2014;234: 398-409
  47. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model
  48. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance
  49. The anti-coagulants ASIS or APC do not protect against renal ischemia/ reperfusion injury
  50. The Effect of Levothyroxine on Expression of Inflammation-Related Genes in Healthy Subjects: A Controlled Randomized Crossover Study
  51. CCAAT-enhancer binding protein delta (C/EBPδ) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy
  52. Protease‐activated receptor‐2 induces migration of pancreatic cancer cells in an extracellular ATP‐dependent manner
  53. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis
  54. Correction for Duitman et al., CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner
  55. Protease-Activated Receptor (PAR)2, but Not PAR1, Is Involved in Collateral Formation and Anti-Inflammatory Monocyte Polarization in a Mouse Hind Limb Ischemia Model
  56. CCAAT/enhancer-binding protein delta (C/EBPδ) plays a minor role in renal host defense against uropathogenicEscherichia coli
  57. CCAAT/Enhancer-Binding Protein δ
  58. Irradiated Riboflavin Diminishes the Aggressiveness of Melanoma In Vitro and In Vivo
  59. CCAAT-Enhancer Binding Protein Delta (C/EBPδ) Protects Against Klebsiella pneumoniae–Induced Pulmonary Infection: Potential Role for Macrophage Migration
  60. Characterization of coagulation factor synthesis in nine human primary cell types
  61. Violacein Induces Death of Resistant Leukaemia Cells via Kinome Reprogramming, Endoplasmic Reticulum Stress and Golgi Apparatus Collapse
  62. Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice: Figure 1–
  63. Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?
  64. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors
  65. The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia – A Prospective Cohort Study
  66. CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner
  67. The protein C pathway in cancer metastasis
  68. Dichotomy in Hedgehog Signaling between Human Healthy Vessel and Atherosclerotic Plaques
  69. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain
  70. Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation
  71. Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis
  72. mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome
  73. Blood coagulation factor Xa as an emerging drug target
  74. The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades
  75. Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury
  76. Human Plasma Very Low Density Lipoprotein Carries Indian Hedgehog
  77. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
  78. Assessing the efficacy of the Hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer
  79. A Low Molecular Weight Heparin Inhibits Experimental Metastasis in Mice Independently of the Endothelial Glycocalyx
  80. Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation
  81. Canonical Hedgehog signaling drives proangiogenic responses in endothelial cells
  82. The role of activated protein C in cancer progression
  83. Experimental and clinical effects of anticoagulants on cancer progression
  84. The Hedgehog morphogen in myocardial ischemia–reperfusion injury
  85. Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver
  86. Protease-Activated Receptor 2 Blocking Peptide Counteracts Endotoxin-Induced Inflammation and Coagulation and Ameliorates Renal Fibrin Deposition in a Rat Model of Acute Renal Failure
  87. Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department
  88. PTX3 predicts severe disease in febrile patients at the emergency department
  89. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir
  90. The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm
  91. Alternatively spliced tissue factor induces angiogenesis through integrin ligation
  92. Insider access: pepducin symposium explores a new approach to GPCR modulation
  93. Letter in response to 'Coagulation and fibrosis in chronic liver disease'
  94. Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus
  95. Long‐term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis
  96. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1–mediated vascular endothelial barrier enhancement
  97. Corrigendum
  98. Activated Protein C Protects Against Myocardial Ischemia/ Reperfusion Injury via Inhibition of Apoptosis and Inflammation
  99. Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation
  100. C-Reactive Protein Elicits White Blood Cell Activation in Humans
  101. Gross deletions/duplications in PROS1 are relatively common in point mutation-negative hereditary protein S deficiency
  102. A mechanism for thrombin-dependent lung metastasis in patients with osteosarcoma
  103. FXa-induced intracellular signaling links coagulation to neoangiogenesis: Potential implications for fibrosis
  104. Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity
  105. Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice
  106. Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease?
  107. Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung
  108. Gene Expression Profiles in Murine Influenza Pneumonia
  109. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease
  110. Gene expression profile comparison of Barrett's esophagus epithelial cell cultures and biopsies
  111. Hypoxia induces a hedgehog response mediated by HIF‐1α
  112. TF:FVIIa‐specific activation of CREB upregulates proapoptotic proteins via protease‐activated receptor‐2
  113. Endogenous Hedgehog Expression Contributes to Myocardial Ischemia-Reperfusion–Induced Injury
  114. Leukotriene Synthesis Is Required for Hedgehog‐Dependent Neurite Projection in Neuralized Embryoid Bodies but Not for Motor Neuron Differentiation
  115. Differential Gene Expression Changes in Children with Severe Dengue Virus Infections
  116. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders
  117. Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation
  118. High factor VIIa levels do not promote tumor metastasis
  119. (Pro-)vitamin D as treatment option for hedgehog-related malignancies
  120. Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites
  121. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation
  122. Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice
  123. Gene Expression Profiling Identifies C/EBPδ as a Candidate Regulator of Endotoxin-induced Disseminated Intravascular Coagulation
  124. Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation
  125. Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation
  126. Protease-Activated Receptors, Apoptosis and Tumor Growth
  127. Factor V Leiden and the etiology of inflammatory bowel disease
  128. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment
  129. Hedgehog Morphogen in Cardiovascular Disease
  130. A dual role for 7-dehydrocholesterol reductase in regulating Hedgehog signalling?
  131. Hedgehog Turns Lipoproteins Into Janus-Faced Particles
  132. Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses
  133. Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin
  134. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice*
  135. Signal transduction induced by activated protein C: no role in protection against sepsis?
  136. Repression of Smoothened by Patched-Dependent (Pro-)Vitamin D3 Secretion
  137. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia*
  138. Alternatively spliced tissue factor in mice: induction by Streptococcus pneumoniae
  139. Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells
  140. Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice
  141. Editorial [Hot Topic: Understanding and Treatment of Diseases in the Haemostatic System (Guest Editor: M.P. Peppelenbosch Co-Editor: C.A. Spek)]
  142. Functional Evolution of Tissue Factor, the Archetype of the Cytokine Receptor Family
  143. Inherited Coagulation Factor VII and X Deficiencies Associated with Severe Bleeding Diathesis: Molecular Genetics and Pathophysiology
  144. RNA-Based Gene Therapy for Haemophilia B
  145. Antiinflammatory Effects of Salmeterol after Inhalation of Lipopolysaccharide by Healthy Volunteers
  146. Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn’s disease patients
  147. Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation*
  148. High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells
  149. Blood coagulation factors as inflammatory mediators
  150. Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice
  151. Inhibition of the Tissue Factor/Factor VIIa Pathway Does Not Influence the Inflammatory or Antibacterial Response to Abdominal Sepsis Induced byEscherichia coliin Mice
  152. Tissue factor
  153. FVIIa:TF Induces Cell Survival via G 12 /G 13 -Dependent Jak/STAT Activation and Bcl XL Production
  154. Concerted action of coagulation factors on cell survival
  155. Blood cell-derived tissue factor influences host response during murine endotoxemia
  156. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis
  157. Hedgehog: an unusual signal transducer
  158. Tissue Factor and Cancer Metastasis: The Role of Intracellular and Extracellular Signaling Pathways
  159. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways
  160. Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis
  161. Regulation of the p21Ras-MAP kinase pathway by factor VIIa
  162. Tissue factor signal transduction in angiogenesis
  163. Effects of IC14, an Anti‐CD14 Antibody, on Coagulation and Fibrinolysis during Low‐Grade Endotoxemia in Humans
  164. Disseminated intravascular coagulation
  165. Type I diabetes: a role for tissue factor in pancreatic islet transplantation?
  166. Microvascular coagulopathy and disseminated intravascular coagulation
  167. Genetic Risk Factors for Venous Thrombosis
  168. Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity
  169. Type-I Protein-C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein-C Gene Promoter
  170. Identification of Evolutionarily Invariant Sequences in the Protein C Gene Promoter
  171. Type I Protein C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein C Gene Promoter
  172. Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites
  173. Genotypic Variation in the Promoter Region of the Protein C Gene Is Associated With Plasma Protein C Levels and Thrombotic Risk